XBRANE BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2295 SEK | +20.54% |
|
+13.61% | -97.70% |
| May. 10 | Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar | MT |
| May. 02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 344M 31.69M | Sales 2025 * | 680M 62.74M | Capitalization | 351M 32.37M |
|---|---|---|---|---|---|
| Net income 2024 * | -186M -17.15M | Net income 2025 * | 104M 9.59M | EV / Sales 2024 * | 0.94 x |
| Net cash position 2024 * | 28.17M 2.6M | Net Debt 2025 * | 116M 10.68M | EV / Sales 2025 * | 0.69 x |
| P/E ratio 2024 * |
-1.7
x | P/E ratio 2025 * |
4.79
x | Employees | 93 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xbrane Biopharma AB
More press releases
| 1 day | +20.54% | ||
| 1 week | +13.61% | ||
| Current month | +6.00% | ||
| 1 month | -39.84% | ||
| 3 months | -81.37% | ||
| 6 months | -98.88% | ||
| Current year | -97.70% |
1 week
0.19
0.26
1 month
0.190.40
Current year
0.1910.84
1 year
0.1989.10
3 years
0.19180.40
5 years
0.19180.40
10 years
0.19180.40
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 19-12-31 | |
Eva Nilsagård
BRD | Director/Board Member | 60 | 19-05-15 |
Kirsti Gjellan
BRD | Director/Board Member | 61 | 22-05-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.2295 | +20.54% | 108,790,000 |
| 24-05-08 | 0.1904 | -4.80% | 10,856,410 |
| 24-05-07 | 0.2 | -1.72% | 7,806,572 |
| 24-05-06 | 0.2035 | +0.74% | 8,327,761 |
| 24-05-03 | 0.202 | -1.70% | 12,159,090 |
Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:29 am EDT
More quotes
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.2295
SEK
Average target price
0.625
SEK
Spread / Average Target
+172.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -97.70% | 32.39M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- XBRANE Stock